Literature DB >> 9870878

Functional analysis of rheumatoid factor-producing B cells from the synovial fluid of rheumatoid arthritis patients.

C C Reparon-Schuijt1, W J van Esch, C van Kooten, E W Levarht, F C Breedveld, C L Verweij.   

Abstract

OBJECTIVE: To understand the regulation of rheumatoid factor (RF) production in rheumatoid arthritis (RA), we studied IgM-RF production by B cells isolated from the synovial fluid (SF).
METHODS: Highly purified SF and peripheral blood (PB) B cells were isolated by negative selection in a fluorescence-activated cell sorter (FACS) and then cultured with either L cells, CD40 ligand (CD40L)-transfected L cells, or type B synoviocytes in the presence or absence of interleukin-2 (IL-2), IL-4, or IL-10. Total IgM and IgM-RF were detected after 14 days by enzyme-linked immunosorbent assay. Enzyme-linked immunospot assays were performed to detect cells that spontaneously produced immunoglobulin. SF B cells were also phenotypically characterized by FACS analysis.
RESULTS: Terminally differentiated CD20-,CD38+ synovial plasma cells (PC) present in the SF of RA patients secreted IgM-RF in the absence of a stimulus. IgM-RF production markedly increased when SF B cells were cultured in the presence of type B RA synoviocytes together with IL-10, but independently of CD40-CD40L interaction. Although CD20-,CD38+ PC could also be demonstrated in SF B cells from patients with other forms of arthritis, IgM-RF production was restricted to the SF B cell cultures of patients with seropositive RA. The frequency of IgM-RF-producing cells among IgM-producing PC in patients with seropositive RA was estimated to be as much as 50%.
CONCLUSION: These data demonstrate that terminally differentiated CD20-,CD38+ IgM-RF-producing B cells are specifically present in the inflamed joints of patients with seropositive RA. There is evidence that the local environment in the rheumatoid joint favors RF production. The relatively high frequency of IgM-RF PC in the SF B cell population provides evidence of a dominant RA-specific antigen-driven response in the development of the synovial PC repertoire.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9870878     DOI: 10.1002/1529-0131(199812)41:12<2211::AID-ART17>3.0.CO;2-O

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  25 in total

1.  Interleukin 10 treatment for rheumatoid arthritis.

Authors:  E W St Clair
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

Review 2.  B-cell involvement in the pathogenesis of RA-is there a contribution of the sympathetic nervous system?

Authors:  Georg Pongratz; Rainer H Straub
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

3.  Selective recruitment of CCR6-expressing cells by increased production of MIP-3 alpha in rheumatoid arthritis.

Authors:  T Matsui; T Akahoshi; R Namai; A Hashimoto; Y Kurihara; M Rana; A Nishimura; H Endo; H Kitasato; S Kawai; K Takagishi; H Kondo
Journal:  Clin Exp Immunol       Date:  2001-07       Impact factor: 4.330

4.  Soluble CD21 in sera and synovial fluid of arthritic patients.

Authors:  Thomas Grottenthaler; Johannes von Kempis; Sigune Goldacker; Harald Illges
Journal:  Rheumatol Int       Date:  2005-03-16       Impact factor: 2.631

5.  Differential requirements for induction of total immunoglobulin and physiological rheumatoid factor production by human peripheral blood B cells.

Authors:  W J Van Esch; C C Reparon-Schuijt; E W Levarht; C Van Kooten; F C Breedveld; C L Verweij
Journal:  Clin Exp Immunol       Date:  2001-03       Impact factor: 4.330

6.  Bcl-x(L) expression in vivo in rheumatoid synovium.

Authors:  S Busteed; M W Bennett; C Molloy; A Houston; M A Stone; F Shanahan; M G Molloy; J O'Connell
Journal:  Clin Rheumatol       Date:  2006-03-30       Impact factor: 2.980

7.  High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis.

Authors:  Francesca Bobbio-Pallavicini; Roberto Caporali; Claudia Alpini; Stefano Avalle; Oscar M Epis; Catherine Klersy; Carlomaurizio Montecucco
Journal:  Ann Rheum Dis       Date:  2006-11-01       Impact factor: 19.103

8.  Interleukin 10 promoter microsatellite polymorphisms are associated with response to long term treatment with etanercept in patients with rheumatoid arthritis.

Authors:  H Schotte; B Schlüter; S Drynda; P Willeke; N Tidow; G Assmann; W Domschke; J Kekow; M Gaubitz
Journal:  Ann Rheum Dis       Date:  2004-09-02       Impact factor: 19.103

Review 9.  The effect of targeted rheumatoid arthritis therapies on anti-citrullinated protein autoantibody levels and B cell responses.

Authors:  S Modi; M Soejima; M C Levesque
Journal:  Clin Exp Immunol       Date:  2013-07       Impact factor: 4.330

10.  Class-switched B cells display response to therapeutic B-cell depletion in rheumatoid arthritis.

Authors:  Burkhard Möller; Daniel Aeberli; Stefan Eggli; Martin Fuhrer; Istvan Vajtai; Esther Vögelin; Hans-Rudolf Ziswiler; Clemens A Dahinden; Peter M Villiger
Journal:  Arthritis Res Ther       Date:  2009-05-06       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.